Grufity logoGrufity logo
Stocks
Funds
Screener
Sectors
Watchlists
CELC

CELC - Celcuity Inc Stock Price, Fair Value and News

$114.23+3.46 (+3.12%)
Market Closed

Price Targets

CELC Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

CELC Price Action

Last 7 days

-0.7%

Last 30 days

9.6%

Last 90 days

8.5%

Trailing 12 Months

1038.9%

CELC RSI Chart

CELC Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

CELC Valuation

Market Cap

5.3B

Price/Earnings (Trailing)

-32.48

EV/EBITDA

-35.25

Price/Free Cashflow

-36.48

MarketCap/EBT

-32.48

CELC Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

CELC Fundamentals

CELC Earnings

Earnings (TTM)

-162.7M

Earnings Growth (Yr)

-47.03%

Earnings Growth (Qtr)

3.23%

CELC Profitability

Return on Equity

-139.12%

Return on Assets

-34.19%

Free Cashflow Yield

-2.74%

CELC Investor Care

Shares Dilution (1Y)

24.62%

Diluted EPS (TTM)

-3.69

About Celcuity Inc

CELC
Celcuity Inc., a clinical stage biotechnology company, focuses on the development of molecularly targeted therapies for cancer patients in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment. Its drug candidate includes Gedatolisib, which selectively targets various class I isoforms of PI3K and mammalian target of rapamycin and focus on the treatment of patients with hormone receptor positive, HER2-negative, and advanced or metastatic breast cancer. The company is also developing CELsignia MP test, a qualitative laboratory developed test that measures HER2, c-Met, and PI3K signaling activity in breast and ovarian tumor cells. It had a license agreement with Pfizer, Inc. for the development and commercialization rights to Gedatolisib. The company was founded in 2011 and is headquartered in Minneapolis, Minnesota.
 CEO
 WEBSITEcelcuity.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES45

Celcuity Inc Frequently Asked Questions

CELC is the stock ticker symbol of Celcuity Inc. Every public company that trades on a stock exchange gets a ticker symbol.

As of Fri Mar 13 2026, market cap of Celcuity Inc is 5.29 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.